Cutaneous mucinosis in a patient taking ustekinumab for palmoplantar psoriasis.
نویسندگان
چکیده
Discrete papular lichen myxedematosus (DPLM), asubset of localized lichen myxedematosus, is a rarecutaneous mucinosis of unknown etiology. We reporta case of a 57-year-old woman with palmoplantarpsoriasis who developed DPLM 8 weeks after addingustekinumab to a long-term course of methotrexate.The patient had previously failed 2 prior tumor necrosisfactor (TNF) inhibitors, adalimumab and etanercept.This case demonstrates an association between TNFinhibitor and ustekinumab use in a psoriasis patientand localized lichen myxedematosus for the secondtime in the literature. The presented case is of interestbecause of the rare diagnosis of DPLM, especially inassociation with the start of the anti-IL 12/23 agentustekinumab. The appearance of DPLM in this settingsuggests a possible etiology for the disease.
منابع مشابه
Can biologic treatment induce cutaneous focal mucinosis?
Skin mucinosis is a rare skin disease which clinically manifests as firm papules and waxy nodules. We report a case of a 66-year-old female psoriatic patient who developed skin mucinosis during biological therapy. Because of a previous lack of response to the local and conventional systemic treatment of psoriasis, the patient received biological therapy (infliximab from June 2008 to May 2009 - ...
متن کامل[Good response of hyperkeratotic palmoplantar psoriasis to ustekinumab].
Although only a small area of the body is affected in palmoplantar psoriasis or psoriasis of the palms and soles, this condition causes considerable functional impairment due to hyperkeratosis, fissures, and erythema, and occasionally inflammation and pustules. These symptoms may seriously interfere with the patient’s quality of life and may be disabling. Moreover, the lack of a standard treatm...
متن کاملRecurrent erythema annulare centrifugum during ustekinumab treatment in a psoriatic patient.
Ustekinumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to the p40 subunit of interleukins 12 and 23. Ustekinumab has been approved for the treatment of moderate-to-severe psoriasis vulgaris and has shown high efficacy with favourable risk and benefit profiles in pivotal trials for both Caucasians (1, 2) and Asians (3). We report here a case of recurrent erythema annulare ...
متن کاملChallenging Regional Psoriasis and Ustekinumab Biotherapy: Impact of the Patterns of Disease
In some patients, psoriasis appears refractory to many treatments, particularly when the disease is confined to some specific body regions. In this respect, palmoplantar psoriasis and palmoplantar pustulosis are possibly related conditions in their immunopathomechanisms involving Il-12, IL-23, and Th17. Nail psoriasis and scalp psoriasis are two other particular psoriasis manifestations. Accord...
متن کاملCombination biologic therapy for the treatment of severe palmoplantar pustulosis
IL: interleukin INTRODUCTION Psoriasis is a common chronic disease andmay be the most prevalent autoimmune disease. The estimated prevalence is 2% to 4% of the global population. Fortunately, providers have a plethora of medications to choose from, but even so, some cases can be very difficult to treat. Herein, we present a challenging case of palmoplantar pustulosis primarily affecting the sol...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Dermatology online journal
دوره 23 3 شماره
صفحات -
تاریخ انتشار 2017